Document is current
Any future updates will be listed below
-
Authors
Guo, Yiling
Pan, Nanfang https://orcid.org/0000-0002-5651-556X
Zou, Yuhan
Long, Yajing
Zhang, Xun https://orcid.org/0009-0008-6567-6702
Li, Qingyuan
Suo, Xueling
Singh, Manpreet K. https://orcid.org/0000-0002-4373-3293
Wang, Song https://orcid.org/0000-0002-4476-1915
Gong, Qiyong https://orcid.org/0000-0002-5912-4871
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82027808)
- License Information
-
More Information
Article History
Received: 26 March 2024
Revised: 16 May 2025
Accepted: 9 June 2025
First Online: 10 July 2025
Competing interests
: Dr. Singh is on the advisory board for Sunovion and Skyland Trail, is a consultant for Johnson and Johnson, Alkermes, Neumora, AbbVie, Karuna Therapeutics, Inc., Boehringer Ingelheim, and Intra-Cellular Therapeutics, Inc. Dr. Singh receives honoraria from the American Academy of Child and Adolescent Psychiatry, and royalties from American Psychiatric Association Publishing and Thrive Global. All other authors declare that they have no competing interests. All other authors declare no conflict of interest.
